Hematopoetic stem cell transplantation in neutrophil disorders: severe congenital neutropenia, leukocyte adhesion deficiency and chronic granulomatous disease.
Until further progress will occur in the field of gene therapy, the only curative treatment available in severe congenital neutropenia, leukocyte adhesion deficiency, and chronic granulomatous disease is allogeneic hematopoietic stem cell transplantation (HSCT). This review summarizes the current data regarding indications for transplantation in each disease, treatment results using related and unrelated donors, as well as toxicity of HSCT in the above diseases.
Elhasid
Ronit
R
Division of Hematology, Rambam Medical Campus, Rappaport School of Medicine, Technion, Bat-Galim, Haifa, Israel. r_elhasid@rambam.health.gov.il
Rowe
Jacob M
JM
D000328:Adult; D002648:Child; D002675:Child, Preschool; D005260:Female; D006105:Granulomatous Disease, Chronic / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods; D006801:Humans; D018370:Leukocyte-Adhesion Deficiency Syndrome / Q000628:therapy*; D008297:Male; D009503:Neutropenia / Q000151:congenital / Q000628:therapy*; D014184:Transplantation, Homologous / Q000009:adverse effects / Q000379:methods; D016896:Treatment Outcome; D055815:Young Adult